FSH receptor genotype and its influence on the results of donor ovarian stimulation using corifollitropin alfa


      Research question

      Does the FSH receptor (FSHR) genotype influence the results of donor ovarian stimulation using corifollitropin alfa?


      A prospective cohort study was performed including 152 oocyte donor ovarian stimulations: group 1 (n = 80) using a single dose of 150 µg of corifollitropin alpha; and group 2 (n = 72) using in addition to corifollitropin alpha, continued stimulation using recombinant FSH 225 IU daily. Allelic discrimination was used to genotype the FSHR p.N680S polymorphism. Linear regression analysis was performed to study the differences between groups.


      No differences in clinical characteristics between genotypes were reported. Overall, the results of ovarian stimulation were better in oocyte donors with SN and NN genotypes compared with SS in terms of the number of retrieved oocytes (15.78 versus 10.83; P = 0.008) and retrieved metaphase II (MII) oocytes (12.34 versus 9.00; P = 0.032). Corresponding differences were also observed in group 1 for the number of retrieved oocytes (13.83 versus 7.50, P = 0.018) and retrieved MII oocytes (10.24 versus 5.42; P = 0.038). However, in group 2 no significant differences were found for oocytes retrieved (17.55 versus 13.06, P = 0.064) or MII oocytes (14.25 versus 11.39; P = 0.12).


      This study suggests that ovarian stimulation protocols with corifollitropin alfa in women with the SS genotypes could be associated with fewer oocytes and MII oocytes retrieved. Despite the fact that corifollitropin alfa has a longer half-life, the results for the SS genotype do not match those for the other genotypes, so other factors must be involved. Therefore, to tailor treatments, it would be advisable to genotype women at p.N680S of the FSHR.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Reproductive BioMedicine Online
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Alviggi C.
        • Conforti A.
        • Santi D.
        • Esteves S.C.
        • Andersen C.Y.
        • Humaidan P.
        • Chiodini P.
        • De Placido G.
        • Simoni M.
        Clinical relevance of genetic variants of gonadotrophins and their receptors in controlled ovarian stimulation: a systematic review and meta-analysis.
        Hum. Reprod. Update. 2018 Sep 1; 24: 599-614
        • Casarini L.
        • Moriondo V.
        • Marino M.
        • Adversi F.
        • Capodanno F.
        • Grisolia C.
        • La Marca A.
        • La Sala G.B.
        • Simoni M.
        FSHR polymorphism p.N680S mediates different responses to FSH in vitro.
        Mol. Cell Endocrinol. 2014 Aug 5; 393: 83-91
        • Conforti A.
        • Tüttelmann F.
        • Alviggi C.
        • Behre H.M.
        • Fischer R.
        • Hu L.
        • Polyzos N.P.
        • Chuderland D.
        • Rama Raju G.A.
        • D'Hooghe T.
        • Simoni M.
        • Sunkara S.K.
        • Longobardi S.
        Effect of Genetic Variants of Gonadotropins and Their Receptors on Ovarian Stimulation Outcomes: A Delphi Consensus.
        Front Endocrinol. (Lausanne). 2022 Feb 1; 12797365
        • Perez Mayorga M.
        • Gromoll J.
        • Behre H.M.
        • Gassner C.
        • Nieschlag E.
        • Simoni M.
        Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype.
        J. Clin. Endocrinol. Metab. 2000 Sep; 85: 3365-3369
        • Verbost P.
        • Sloot W.N.
        • Rose U.M.
        • de Leeuw R.
        • Hanssen R.G.
        • Verheijden G.F.
        Pharmacologic profiling of corifollitropin alfa, the first developed sustained follicle stimulant.
        Eur. J. Pharmacol. 2011 Jan 25; 651: 227-233


      Belén Lledó received her PhD in molecular biology from the University of Alicante, Spain. In 2004 she moved to Instituto Bernabeu and is now Director of the Molecular Biology Department. She has received prizes at different congresses and published tens of papers on genetic variants in infertility and preimplantation genetic diagnosis.